Sandoz launches Enzeevu aflibercept biosimilar in US with new private-label distribution agreement

Sandoz has launched its interchangeable aflibercept biosimilar Enzeevu in the United States and announced a multi-year private-label distribution arrangement, expanding commercial competition in treatments for retinal vascular diseases.
Sandoz announced on 16 November 2026 that it had commercially launched Enzeevu (aflibercept-abzv), an interchangeable biosimilar to Eylea, in the United States as a 2 mg pre-filled syringe for approved ophthalmic indications including neovascular age-related macular degeneration and diabetic macular oedema.
The company also disclosed a multi-year private-label distribution agreement establishing an additional US commercial channel from mid-2027, with committed volumes expected from the second half of that year; Enzeevu originally received FDA approval in August 2024, so the November announcement concerns market launch and distribution rather than a newly granted regulatory approval.
Field | Content |
Article Type | Industry Updates |
Company | Sandoz |
Product Brand Name | Enzeevu |
Active Ingredient | Aflibercept-abzv |
Product Classification | Interchangeable biosimilar |
Reference Product | Eylea |
Announcement Date | 16 November 2026 |
Event Type | US commercial product launch and distribution agreement |
Commercial Launch Market | United States |
Commercial Launch Status | Launched |
Original FDA Approval Date | August 2024 |
New FDA Approval Announced | No |
Therapeutic Area | Ophthalmology |
Disease Category | Retinal vascular diseases |
Indication One | Neovascular age-related macular degeneration |
Indication One Abbreviation | nAMD |
Indication Two | Diabetic macular oedema |
Product Presentation | 2 mg pre-filled syringe |
Biosimilar Regulatory Status | FDA-approved interchangeable biosimilar |
Distribution Agreement Type | Multi-year private-label agreement |
Additional Commercial Channel | US private-label distribution |
Private-Label Channel Start | Mid-2027 |
Expected Committed Volumes | From the second half of 2027 |
Distribution Partner | Not specified in supplied summary |
Agreement Financial Terms | Not disclosed in supplied summary |
Commercial Strategy | Expand access and distribution of an interchangeable ophthalmic biosimilar |
What Happened | Sandoz launched Enzeevu in the US and announced an additional private-label commercial distribution arrangement. |
Why It Matters | The launch adds a commercial biosimilar alternative in the US market for widely used retinal disease treatments. |
Commercial Significance | Establishes immediate US market presence with a further distribution channel planned for 2027. |
Access Significance | Additional biosimilar competition may broaden treatment and purchasing options for retinal disease care. |
Regulatory Clarification | The FDA approved Enzeevu in August 2024; November 2026 marks commercial launch rather than a new approval. |
Distribution Clarification | The private-label channel is expected to begin in mid-2027, with committed volumes from the second half of that year. |
Key Takeaway | Enzeevu is commercially available in the US, with Sandoz planning an additional private-label distribution channel in 2027. |
What to Watch | US market uptake, reimbursement, pricing competition, private-label rollout and committed distribution volumes. |
Primary Source | Sandoz |
Primary Source URL | https://www.sandoz.com/sandoz-launches-enzeevu-us-and-announces-key-private-label-agreement-expanding-treatment-choice/ |
Submitted Source | EQS News |
Submitted Source URL | https://www.eqs-news.com/news/ad-hoc/sandoz-launches-enzeevu-in-the-us-and-announces-key-private-label-agreement-expanding-treatment-choice-for-patients-with-retinal-diseases/c8143ba5-e941-4ff0-b594-c7355a3372fa_en |
Relevant Date | 16 November 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com

留言